Inferring Drug Set and Identifying the Mechanism of Drugs for PC3

Int J Mol Sci. 2024 Jan 7;25(2):765. doi: 10.3390/ijms25020765.

Abstract

Drug repurposing is a strategy for discovering new applications of existing drugs for use in various diseases. Despite the use of structured networks in drug research, it is still unclear how drugs interact with one another or with genes. Prostate adenocarcinoma is the second leading cause of cancer mortality in the United States, with an estimated incidence of 288,300 new cases and 34,700 deaths in 2023. In our study, we used integrative information from genes, pathways, and drugs for machine learning methods such as clustering, feature selection, and enrichment pathway analysis. We investigated how drugs affect drugs and how drugs affect genes in human pancreatic cancer cell lines that were derived from bone metastases of grade IV prostate cancer. Finally, we identified significant drug interactions within or between clusters, such as estradiol-rosiglitazone, estradiol-diclofenac, troglitazone-rosiglitazone, celecoxib-rofecoxib, celecoxib-diclofenac, and sodium phenylbutyrate-valproic acid.

Keywords: NMF; drug interaction; feature selection.

MeSH terms

  • Celecoxib
  • Diclofenac*
  • Estradiol
  • Humans
  • Male
  • PC-3 Cells
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / genetics
  • Rosiglitazone

Substances

  • Celecoxib
  • Diclofenac
  • Estradiol
  • Rosiglitazone